Merck Sharp + Dohme Corp.

Dogwood Pharmaceuticals, Inc.

Other

Avalon Pharmaceuticals, Inc.

Yi Zang

Weiguo Liu

Wanying Sun

Wieslaw Marek Cholody

Janak Khimchand Padia

Jeffrey William Strovel

Karina Zuck

Jeffrey W H Watthey

Zoe Ohler

Sheela Chellappan

Tesfaye Biftu

Xianhai Huang

Scott D Edmondson

Haifeng Tang

Santhosh Francis Neelamkavil

Anthony K Ogawa

Eric Mertz

Weidong Pan

Min K Park

Feng Ye

Debra L Ondeyka

Jiafang He

Rudrajit Mal

Gene Ohler

Amjad Ali

Alexander Pasternak

Sung-Sau So

Paul E Finke

Jianming Bao

F Anthony Romero

Jinlong Jiang

Feroze Ujjainwalla

Fa-Xiang Ding

Harold B Wood

Ying-Duo Gao

Zhuyan Guo

Helen Y Chen

Lin Chu

Alan W Hruza

Rongze Kuang

Yan Guo

James Francis Dropinski

Linda Brockunier

Christopher W Plummer

Petr Vachal

Joseph Leslie Duffy

John J Acton, Iii

Guizhen Dong

Heping Wu

Deyou Sha

Fengqi Zhang

Vincent Colandrea

Edward C Sherer

Sriram Tyagarajan

Ning Shao

Alexander J Kim

Remond Moningka

Hongwu Wang

Zahid Hussain

Revathi Reddy Katipally

Michael A Plotkin

Aaron Zwicker

Patrick Shao

Andrew F Nolting

Vincent J Colandrea

Norman E Ohler

Joseph L Duffy

Janak Padia

Min Park

Jeffrey Strovel

John J Iii Acton

Jeffrey WH Watthey

Zahid Hussian

Anthony Romero

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic. 

Chromane monobactam compounds for the treatment of bacterial infections

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, Q, A, M, W, Rand Rare as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Factor XIa inhibitors

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/&#x3b2;-catenin signaling pathway, and serve to reduce &#x3b2;-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. 

Cyclic amine substituted heterocyclic CETP inhibitors

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 

Spiroxazolidinone compounds

Growing community of inventors

Princeton Junction, NJ, United States of America

Yi Zang